COVID-19 Safety Measures Announced for Biomarker Study

COVID-19 Safety Measures Announced for Biomarker Study

282419

COVID-19 Safety Measures Announced for Biomarker Study

Mitsubishi Tanabe Pharma America (MTPA) is taking proactive measures to address patient safety in its REFINE-ALS biomarker study during the COVID-19 pandemic. The company announced revisions to the study’s protocol that give participants the option to participate virtually, through the use of telemedicine (medical care delivered virtually) and home health agencies instead of hospital or in-office visits. “In an effort to address the evolving concerns of the ALS community this year, we made it a…

You must be logged in to read/download the full post.